Swedish Orphan Biovitrum AB (Sobi) shed some old skin to grow some new by expanding its Novimmune SA deal by acquiring emapalumab (NI-0501, branded as Gamifant) and all its related assets. Sobi also gets all emapalumab employees involved in the drug's clinical and biopharmaceutical development.